demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 all comers
COVID 19 all comers
antiviral and associated therapy
chloroquine and derivatives
chloroquine Chen, ChiCTR2000030054 - Chloroquine
hydroxychloroquine NCT04376814-Group A Gautret et al. NCT04376814-Group A ChiCTR2000030054-HCQ ... IRCT20150808023559N20 NOR-Solidarity ... IRCT20150808023559N20
darunavir cobicistat Jun C
favipiravir Cai -FAVIPIRAVIR jRCTs041190120 Lou ... NCT04376814-Group A IRCT20150808023559N20 Calik Chang Chen et al. NCT04310228-FAVI ... IRCT20150808023559N20 Cai -FAVIPIRAVIR NCT04376814-Group A
hydroxychloroquine plus macrolides Magagnoli ...
nirmatrelvir / ritonavir (Paxlovid) EPIC-SR
remdesivir Andreas ... Norwegian NOR study ...
umifenovir (arbidol) ELACOI ...

5 studies excluded by filtering options 2

4899 ChiCTR2000029826 (Cancelled by the investigator), 0 210excludedrisk of bias not avaialble
4905 ChiCTR2000029975, 0 2300excludednot a RCTrisk of bias not avaialble
4987 CloroCOVID19, 2020 213excludedhigh risk of bias
5288 Barbosa, 2020 2130excludednot a RCTrisk of bias not avaialble
5351 Mallat, 2020 2130excludednot a RCTrisk of bias not avaialble